Covid-19

KANSAS FEDERAL COURT DISMISSES PFIZER’S EFFORTS TO STOP THE STATE’S LAWSUIT

Kansas Attorney General Kris Kobach is celebrating a procedural win in his lawsuit against Pfizer, but the judge’s ruling only addressed jurisdiction—not the vaccine’s safety. The case, criticized by health experts as baseless, now returns to Kansas state court.

Published

1 year ago

May 16, 2025

Emmanuel Abiodun

A federal judge has ruled that the state of Kansas can proceed with its lawsuit against Pfizer in state court, denying the pharmaceutical company’s attempt to move the case to federal jurisdiction. The decision marks an early procedural win for Kansas Attorney General Kris Kobach, who filed the lawsuit in 2023 in Thomas County, Kansas.

The lawsuit accuses Pfizer of engaging in deceptive marketing practices related to its COVID-19 vaccine. Specifically, it alleges that the company misled the public about the vaccine’s safety and effectiveness, concealed critical data, and downplayed potential risks such as myocarditis and complications during pregnancy. The complaint further claims that Pfizer worked to suppress dissenting information on social media and failed to disclose material facts that would have affected public perception.

In his ruling, U.S. District Judge Daniel D. Crabtree rejected Pfizer’s arguments that the case belongs in federal court because of the company’s partnership with the federal government during Operation Warp Speed. Crabtree held that the state’s claims are grounded in Kansas consumer protection law and do not hinge on federal statutes, thus justifying their place in state court.

The judge also dismissed Kobach’s request to have Pfizer pay the state’s legal fees related to the jurisdictional dispute.

ALSO READ : Whalar group secures $400 million valuation in funding round led by Marc Benioff

Pfizer has strongly denied the allegations and maintained that its COVID-19 vaccine met all regulatory standards. The company points to the vaccine’s emergency use authorization granted by the U.S. Food and Drug Administration in December 2020 and full FDA approval in August 2021. Health authorities, including the CDC and WHO, continue to affirm the vaccine’s safety and effectiveness.

Nevertheless, the case’s return to Kansas state court means it will move forward, and its outcome could influence similar litigation efforts in other states.